UPDATE 1-Samsung, Biogen version of AbbVie's Humira approved in Europe


A biosimilar version of AbbVie Inc's blockbuster arthritis drug Humira, produced by a joint venture of Biogen Inc and Samsung Biologics, was approved by European Union regulators, the partners said on Thursday. The new drug, Imraldi, marks the third European Commission approval for "biosimilar" versions from the joint venture, Samsung Bioepis, of drugs in a class known as TNF inhibitors.



from Biotech News